Inovio Pharmaceuticals (NYSE MKT: INO) reported Monday that preliminary results from a phase I trial of its H1N1 universal flu vaccine in elderly patients showed a doubling of the response rate of subjects generating infection-preventing antibodies. 

Inovio Pharmaceuticals (NYSE MKT: INO) says that its synthetic and therapeutic hepatitis B vaccine generated strong T cell responses that eliminated targeted liver cells in mice, pointing to the vaccine's potential to clear the infection and prevent liver cancer. 

Inovio's SynCon® vaccines are designed to provide two capabilities not achievable with conventional vaccines: stimulation of T-cell immune responses to provide therapeutic capabilities, and universal cross-strain protection and treatment against known as well as newly emergent unmatched strains of pathogens. 

Inovio Pharmaceuticals (NYSE MKT:INO) (AMEX:INO) said today that its subsidiary, VGX Animal Health, has received approval to market LifeTide SW 5.0, what it called the world's first approved growth hormone releasing hormone (GHRH) therapy for food animals, in New Zealand. 

Inovio Pharmaceuticals (AMEX:INO) saw its stock surge this afternoon after it showed for the first time that its therapeutic synthetic vaccine VGX-3100 can kill cells changed by the human papillomavirus (HPV) into precancerous cervical dysplasias. 

U.S. markets rose on Friday after positive economic reports that boosted investor sentiment to recover losses from the previous session, with benchmark indexes set to record their fourth straight week of gains and close at another set of record highs. 

With a fresh round of financing at its disposal, Sirona Biochem (CVE: SBM) is poised to follow through with its strategy of pursuing patent opportunities, partners and joint ventures. Earlier this month, the Vancouver-based biotechnology firm announced it had raised nearly $1 million, which brings its total debt and equity financing to $2.4 million so far this year.

Soligenix (OTCQB:SNGX), a biopharmaceutical company focused on products for inflammatory diseases and biodefense countermeasures, has taken yet another step toward advancing one of its drugs, saying it has started the first clinical study for the development of SGX203, its treatment for pediatric Crohn's disease.

Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), revealed today results from its Vascazen "Reveal" clinical trial, saying the product was "highly effective" in correcting an Omega-3 deficiency. 

U.S. stock futures rose slightly on Tuesday amid corporate earnings and ahead of consumer credit data, looking set to extend gains that took benchmark indexes to record highs in the previous session.